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ABSTRACT Select methicillin-susceptible Staphylococcus aureus (MSSA) strains may
produce -lactamases with affinity for first-generation cephalosporins (1GCs). In the
setting of a high inoculum, these -lactamases may promote the cleavage of 1GCs,
a phenomenon known as the cefazolin inoculum effect (CzIE). We evaluated the
prevalence and impact of CzIE on clinical outcomes among MSSA acute hematoge-
nous osteomyelitis (AHO) cases. MSSA AHO isolates obtained from two children’s
hospitals between January 2011 and December 2018 were procured through ongo-
ing surveillance studies. Isolates were tested for CzIE via a broth macrodilution assay
using an inoculum of 107 CFU/ml; CzIE was defined as a cefazolin MIC of 16 g/ml.
Isolates were characterized by accessory gene regulator group (agr). The progression
from acute to chronic osteomyelitis was considered an important outcome. A total
of 250 cases with viable isolates were included. Notably, 14.4% of isolates exhibited
CzIE with no observed temporal trend; and 4% and 76% of patients received a 1GC
as an empirical and definitive therapy, respectively. CzIE isolates were more often re-
sistant to clindamycin, belonged to agrIII, and associated with the development of
chronic osteomyelitis. In multivariable analyses, agrIII, multiple surgical debride-
ments, delayed source control, and CzIE were independently associated with pro-
gression to chronic osteomyelitis. A higher rate of chronic osteomyelitis was ob-
served with CzIE isolates regardless of definitive antibiotic choice. CzIE is exhibited
by 14.4% of MSSA AHO isolates in children. CzIE is independently associated with
progression to chronic osteomyelitis in cases of AHO irrespective of final antibiotic
choice. These data suggest that negative outcomes reported with CzIE may more ac-
curately reflect strain-dependent virulence factors rather than true antibiotic failure.
KEYWORDS osteomyelitis, cefazolin inoculum effect, MSSA, pediatric, cephalosporin
The agents of choice in the treatment of methicillin-susceptible Staphylococcusaureus (MSSA) infections are -lactam antimicrobials (1, 2). A number of recent
studies have illustrated that the use of first-generation cephalosporins (1GCs; e.g.,
cefazolin) is associated with similar or, in some reports, improved outcomes compared
with antistaphylococcal penicillins (e.g., nafcillin and oxacillin) in the treatment of
serious MSSA infections (3–5). Moreover, both cefazolin and nafcillin/oxacillin are
regarded as appropriate agents in national guidelines for the treatment of serious
MSSA infections, such as bacteremia and endocarditis (2, 6, 7). Notably, 1GCs are
associated with fewer drug-related adverse events than nafcillin/oxacillin, including less
instances of infusion reactions, rash, neutropenia, acute kidney injury, and transaminase
elevation (3, 8).
The vast majority of S. aureus strains possess a -lactamase encoded by blaZ (9–11).
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S. aureus -lactamases were initially characterized serologically into types A to D. The
various -lactamase types have subtle differences in kinetics and substrate affinity (12,
13). Some S. aureus -lactamase types have a degree of affinity for 1GCs, with the
highest affinity among types A and C (13, 14). Despite this, drug inactivation in vivo is
not believed to typically occur to a clinically meaningful degree.
As early as the 1970s, a subset of MSSA isolates was noted to exhibit striking
elevations in 1GC MICs when a greater than standard inoculum was used in suscepti-
bility testing (15, 16). This phenomenon, which affects 1GCs (including cefazolin and
cephalexin) but not nafcillin/oxacillin, is referred to as the cephalosporin (or cefazolin)
inoculum effect (CzIE) (17, 18). In a recent study of Argentinian adults with MSSA
bacteremia treated with 1GC, it was noted that CzIE was an independent predictor of
30-day all-cause mortality (9). Such observations continue to raise questions regarding
the efficacy of 1GCs in severe MSSA infections.
There are no data available on the prevalence or clinical significance of CzIE in a
pediatric population. Acute hematogenous osteomyelitis (AHO) is the most common
invasive staphylococcal infection in children. S. aureus AHO is frequently associated
with large deep-seated purulent collections which require surgical debridement (19, 20)
and as such may be regarded as a high inoculum infection. As the proportion of
invasive S. aureus disease attributable to MSSA among children in the United States
continues to rise (19, 21, 22), understanding the impact of CzIE on clinical outcomes will
be of increasing importance.
The primary goals of this study were to (i) describe the frequency and characteristics
of CzIE among MSSA AHO isolates at two children’s hospitals and (ii) assess the impact
of CzIE on AHO outcomes. The progression from acute to chronic osteomyelitis was
considered a clinically significant outcome which is regarded as a surrogate for treat-
ment failure.
RESULTS
A total of 250 viable MSSA AHO isolates from January 2011 to December 2018 met
all inclusion criteria. Of those, 208 isolates were obtained from Texas Children’s Hospital
(TCH) and 42 were from St. Louis Children’s Hospital (SLCH). The median patient age
was 9.3 years (interquartile range [IQR], 5.4 to 12.2 years) (Table 1). Overall, 64.4% of
cases were associated with isolated osteomyelitis and 35.6% with osteomyelitis and
concomitant septic arthritis. A total of 57.6% of cases had bacteremia. Surgical drain-
age/debridement was performed in 63.2% of cases and 18% underwent 2 temporally
distinct surgical procedures during the index admission.
Significant differences in patient demographics, disease presentation, and manage-
ment were noted between contributing institutions (see Table S1 in the supplemental
material). MSSA isolates from both institutions were similar in terms of clindamycin
resistance, accessory gene regulator (agr) group, and Panton-Valentine leucocidin (PVL)
carriage.
Medical therapy. Overall, the most common empirical antibiotic choices were
clindamycin monotherapy (87, 34.5%) and vancomycin monotherapy (75, 30%); 38
patients (15.2%) received empirical vancomycin and nafcillin combination therapy. Only
10 subjects (4%) received a 1GC for empirical therapy with or without other agents. A
full list of empirical therapy regimens is provided in Table S2 in the supplemental
material.
A total of 189 patients (76%) received a 1GC for definitive therapy, 114 patients
(45.6%) were prescribed cephalexin, 74 patients (29.6%) received cefazolin, and 1
patient received cefadroxil. Patients received a median of 4 days of non-1GC therapy
(IQR, 3 to 6 days) prior to transitioning to 1GC. Specific dosing regimens of cephalo-
sporins are provided in Table S3 in the supplemental material; patients were most
commonly prescribed 100 mg/kg of body weight per day of cefazolin or cephalexin
divided every 8 h. Other commonly used agents for definitive therapy included nafcillin
(37, 14.8%) and clindamycin (14, 5.6%).
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Overall, 127 patients (50.8%) were discharged on oral antibiotics. These patients
received a median of 6 days of intravenous antibiotics prior to transition to oral
antibiotics (IQR, 4 to 8 days). The rate of oral antibiotic use increased during the study
period from 19% in 2011 to 75% in 2018 (P  0.003).
Cefazolin inoculum effect. Using a standard inoculum (105 CFU/ml), all isolates had
a cefazolin MIC of 2 g/ml (Fig. 1). When tested with a high inoculum (107 CFU/ml),
90 isolates (36%) exhibited a 4-fold increase in cefazolin MIC, although the majority
had a high inoculum MIC of 4 g/ml (53/90, 58.9%). Overall, 36 MSSA isolates (14.4%)
exhibited significant CzIE in vitro, defined as a high inoculum MIC of 16 g/ml (range,
16 to 128 g/ml) (9, 23). CzIE isolates were more likely to be clindamycin resistant (25%
versus 9.3%, P  0.02) and to belong to agrIII (52.7% versus 9.8%, P  0.001) than
isolates not exhibiting CzIE (Table 2). There was no temporal trend with regard to the
proportion of isolates exhibiting CzIE in the study period. A similar proportion of
isolates from each contributing hospital exhibited CzIE. Additionally, among the subset
tested, CzIE isolates exhibited higher cephalexin MICs when using a 107-CFU/ml
inoculum than non-CzIE isolates (Fig. 2).
Infections caused by isolates with and without CzIE were similar in terms of patient
age, demographics, the presence of bone abscesses, and the need for surgery and
medical management (Table 2). Patients with CzIE isolate infections less often under-
went multiple surgical debridement procedures (5.6% versus 20.1%, P  0.04). A similar
proportion of patients in both groups received definitive treatment with a 1GC. A
greater proportion of infections caused by isolates with CzIE evolved into chronic
osteomyelitis by the time of last follow-up (13.8% versus 3.7%, P  0.03).
Chronic osteomyelitis. Overall, 13 (5.2%) MSSA osteoarticular infections (OAIs)
progressed to chronic osteomyelitis. With regard to characteristics of the infecting
organisms themselves, the development of chronic osteomyelitis was associated with
isolates exhibiting CzIE and those belonging to agrIII in univariable analyses (Table 3);
there was no association with the carriage of PVL and development of chronic osteo-
myelitis.
TABLE 1 Characteristics of study groupa
Characteristic Clinical valuesb
Age (yrs) 9.3 (5.4–12.2)






Unknown/not disclosed 8 (3.2)
Hispanic ethnicity 71 (28.4)
Chronic medical comorbidities 15 (6)
Duration of symptoms on presentation (days) 5 (3–7)
Isolated osteomyelitis 162 (64.4)
Osteomyelitis with concomitant septic arthritis 88 (35.2)
Subperiosteal/intraosseous abscess 108 (43.2)
Surgery performed 158 (63.2)
Positive blood culture 144 (57.6)
ICUd admission 13 (5.2)
Length of stay (days) 6 (5–9)
Total duration of therapy (days) 42 (31–56)
Total duration of follow-up (days) 92.5 (37–324)
Progression to chronic osteomyelitis 13 (5.2)
an  250.
bAll continuous variables are presented as medians with interquartile ranges; categorical variables are
presented as n (%).
cOther with regard to race includes Native American/Alaskan Native, Native Hawaiian/Pacific Islander, and
self-identified multiple races given the relatively small number of patients.
dICU, intensive care unit.
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Patients who developed chronic osteomyelitis more often had subperiosteal/in-
traosseous abscesses (69.2% versus 41.8%, P  0.08, Table 4), bacteremia (84.6% versus
56.1%, P  0.048), multiple surgical debridements during the period of acute infection
(53.8% versus 15.8%, P  0.003), and experienced a delay in first source control
(3 days until source control [24]; 30.7% versus 9.2%, P  0.03). There were no signif-
icant associations observed between antibiotic choices, route or duration of therapy,
and progression to chronic osteomyelitis. With regard to 1GCs, there was no observed
association with specific agents or dosing regimens and chronic osteomyelitis (see
Table S4 in the supplemental material).
The results of multivariable analyses revealed significant associations between
progression to chronic osteomyelitis and multiple surgical debridements (P  0.01),
delayed source control (P  0.03), agrIII (P  0.04), and CzIE (P  0.03) (Table 5). When
CzIE alone was substituted with CzIE and 1GC treatment and forced into the logistic
regression model, we observed no association with chronic osteomyelitis (P  0.3).
Antibiotic choice, inoculum effect, and outcomes. Subjects were stratified by
inoculum effect status to assess the effect of definitive antibiotic choice on the
development of chronic osteomyelitis. A 1GC was definitive therapy in 30/36 (83.3%)
CzIE subjects and 159/214 (74.2%) of non-CzIE subjects (P  0.29). Isolates with CzIE
were associated with higher rates of progression to chronic osteomyelitis than those
without CzIE regardless of whether treatment was with a 1GC or a non-1GC regimen
(Fig. 3).
Whole-genome sequencing. Whole-genome sequencing was performed on all 36
isolates exhibiting CzIE to determine sequence types (STs) and -lactamase types (Fig.
4). The majority of cases were ST30 (19/36, 52.7%), with the next most common being
ST8 (5/36, 13.9%). Among ST30, 15/19 (78.9%) belonged to agrIII. Type A -lactamase
was most common, being noted in 27/36 cases (75%), followed by type C (8/36, 22.2%)
and type B (1/36, 2.7%). Type A -lactamase predominated in ST30 strains (18/19,
94.7%), while all ST8 strains possessed type C -lactamase.
DISCUSSION
In the treatment of serious MSSA infections outside the central nervous system,
1GCs are generally regarded as equally efficacious as antistaphylococcal penicillins (5).
FIG 1 Cefazolin MICs. Broth macrodilution MICs for cefazolin using standard (105 CFU/ml) (A) and high inocula (107 CFU/ml) (B). CzIE,
cefazolin inoculum effect.
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Controversy has surrounded the clinical impact of CzIE and how this phenomenon
should influence therapeutic decisions (25). A number of studies in animal models as
well as at least one clinical study in adults suggest that the presence of CzIE reduces the
efficacy of 1GC therapy (9, 26). However, other observational clinical studies have not
illustrated an increased risk of treatment failure or attributable mortality with CzIE
infection (10, 27). Here, we present the first study of the epidemiology and impact of
CzIE among pediatric osteoarticular infections, demonstrating an association between
infections caused by CzIE strains and progression to chronic osteomyelitis, a surrogate
for treatment failure.
Across published studies, the definition of CzIE varies. A cefazolin MIC of 16 g/ml
has previously been used by CLSI to define cefazolin resistance in S. aureus (28) and
may represent a clinically meaningful measure; this definition was used in our study as
by others (9). In our study population, 14.4% of MSSA isolates exhibited CzIE. In
contrast, 55% of MSSA bloodstream isolates exhibited CzIE in a study from Argentina
(9) using an identical definition. When applying the definition of a 4-fold increase in
MIC comparing high and standard inoculums, 36% of our isolates exhibited CzIE. In a
TABLE 2 Comparison of infections by isolates with and without CzIE
Characteristic
Clinical and microbiologic valuesa related to isolates:
P valueWith CzIE (n  36) Without CzIE (n  214)
Age (yrs) 10.4 (6.9–11.9) 9.1 (5.1–12.2) 0.38
Female gender 13 (36.1) 87 (40.6) 0.71
Race 0.82
White 30 (83.3) 153 (71.4)
Black 5 (13.8) 43 (20.1)
Asian 0 6 (2.8)
Otherb 0 5 (2.3)
Unknown/not disclosed 1 (2.7) 7 (3.3)
Hispanic ethnicity 10 (27.8) 61 (28.5) 1
Duration of symptoms on presentation (days) 4.5 (2–7) 5 (3–7) 0.52
Admission CRPc (mg/dl) 4.6 (3.8–7.7) 6.6 (3.7–15.5) 0.21
Multifocal infection 3 (8.3) 7 (3.3) 0.16
Subperiosteal/intraosseous abscess 17 (47.2) 85 (39.7) 0.46
Maximum abscess diameterd (cm) 2.9 (1.1–4) 3 (1.5–5.8) 0.3
Surgical procedure performed 20 (55.5) 136 (63.5) 0.36
2 surgical procedures performede 2 (5.6) 43 (20.1) 0.04
Delayed first source controlf 5 (13.8) 23 (10.7) 0.57
ICU admission 1 (2.7) 12 (5.6) 0.7
Positive blood culture 26 (72.2) 118 (55.1) 0.07
Duration of bacteremia (days) 1 (1–2) 1 (1–2) 0.39
Duration of fever after admission (days) 3 (2–4) 3 (2–4) 0.37
Definitive treatment with 1GC 30 (83.3) 159 (74.3) 0.29
Discharge on oral antibiotics 20 (55.6) 105 (49.1) 0.58
Length of stay (days) 6 (5–10) 6 (5–9) 0.9
Duration of follow-up (days) 68 (39–494) 77 (35–247) 0.32
Progression to chronic osteomyelitis 5 (13.8) 8 (3.7) 0.03
Clindamycin resistance 9 (25) 20 (9.3) 0.01
PVLg positive 5 (13.8) 47 (21.9) 0.38
Vancomycin MIC of 1 g/ml 12 (33.3) 100 (46.7) 0.15
agrIh 13 (36.1) 140 (65.4) 0.001
agrII 2 (5.6) 31 (14.5) 0.19
agrIII 19 (52.7) 21 (9.8) 0.001
agrIV 1 (2.7) 8 (3.7) 1
agr nontypeable 1 (2.7) 14 (6.5) 0.7
aAll continuous variables are presented as medians with interquartile ranges; categorical variables are presented as n (%).
bOther with regard to race includes Native American/Alaskan Native, Native Hawaiian/Pacific Islander, and self-identified multiple races.
cCRP, C-reactive protein.
dOnly 61 cases had abscess size documented.
eThe number of surgical procedures performed refers only to those performed during the index admission.
fDelayed source control was defined as 3 calendar days from the time of admission until first surgical source control.
gPVL, Panton-Valentine leucocidin.
hagr refers to accessory gene regulator group.
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recent study of MSSA isolates from four hospitals in the Chicago area, Wang et al.
reported that 16.7% of all isolates exhibited a 4-fold increase in cefazolin MIC compar-
ing high and standard inoculums (29). Using a similar definition of CzIE, investigators at
Emory University reported CzIE in 27% of MSSA bloodstream isolates obtained from
adults, although only 4.3% had a cefazolin MIC of 16 g/ml (11). Such findings
suggest a degree of geographic variability in CzIE prevalence.
We also observed an association with CzIE and clindamycin resistance, occurring in
25% of isolates. Even though -lactam antibiotics are clearly preferred for MSSA, this is
notable, as clindamycin is commonly used empirically in suspected AHO. While the
exact reasons for this association are unclear, such a finding was previously reported by
investigators in Korea who found that 21% of CzIE isolates exhibited concomitant
clindamycin resistance; this was particularly common among CzIE isolates with type A
-lactamase occurring in 44% of them (27). These findings may be associated with the
underlying strain type. Wi et al. reported that among Korean CzIE isolates, 75%
belonged to agrIII (30). Similar to these data, we found that CzIE was disproportionately
occurring in agrIII isolates in our North American population.
FIG 2 Cephalexin MICs. Broth macrodilution MICs for cefazolin using standard (105 CFU/ml) (A) and high inocula (107 CFU/ml) (B).
TABLE 3 Univariable associations of chronic osteomyelitis and microbiologic and molecular characteristics of MSSA
Characteristic of MSSA
No. (%) of patients with:
P value
Progression to chronic
osteomyelitis (n  13)
No progression to chronic
osteomyelitis (n  237)
Clindamycin resistant 3 (23.1) 26 (10.9) 0.18
CzIEa 5 (38.5) 31 (13.1) 0.02
 4-fold increase in cefazolin MIC with high inoculum 6 (46.2) 84 (35.4) 0.55
Vancomycin Etest MIC of 1 g/mlb 3 (23.1) 109 (45.9) 0.15
PVL positive 5 (38.5) 47 (19.8) 0.15
agrI 6 (46.1) 147 (62) 0.26
agrII 2 (15.4) 31 (13.1) 0.67
agrIII 4 (30.7) 36 (15.2) 0.1
agrIV 0 9 (3.8) 1
agr nontypeable 1 (7.6) 14 (5.9) 0.56
aCzIE was defined as a high-inoculum cefazolin MIC of 16 g/ml.
bNo isolate had a vancomycin Etest MIC of 2 g/ml.
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In multivariable analyses, CzIE was an independent predictor for the progression of
acute osteomyelitis to chronic infection, a proxy for treatment failure. This finding is
consistent with that of a recent study in adults with MSSA bacteremia which suggested
an association with CzIE and mortality (9). Importantly, we found that children with
TABLE 4 Univariable associations of chronic osteomyelitis, patient characteristics, and management
Characteristic
Valuesa for patients with:
P value
Progression to chronic
osteomyelitis (n  13)
No progression to chronic
osteomyelitis (n  237)
Age (yrs) 8.9 (4.2–13.9) 8.3 (3.1–11.6) 0.26
Female gender 4 (30.7) 96 (40.5) 0.57
Race 0.9
White 10 (76.9) 173 (72.9)
Black 3 (23.1) 45 (18.9)
Asian 0 6 (2.5)
Otherb 0 5 (2.1)
Unknown/not disclosed 0 8 (3.4)
Hispanic ethnicity 2 (15.4) 69 (29.1) 0.35
Duration of symptoms on presentation (days) 5 (4–20) 5 (3–7) 1
Multifocal infection 0 11 (4.6) 1
Subperiosteal/intraosseous abscess 9 (69.2) 99 (41.8) 0.08
Maximum abscess diameterc (cm) 4.8 (2.9–6.1) 3 (1.4–4.4) 0.21
ICU admission 2 (15.4) 11 (4.6) 0.14
Positive blood culture 11 (84.6) 133 (56.8) 0.048
Duration of bacteremia (days) 1 (1–1) 1 (1–2) 0.9
Duration of fever after admission (days) 1 (0–2) 2 (0–3) 0.11
Medical management
Empiric therapy 0.18
Clindamycin monotherapy 3 (23.1) 84 (35.4)
Vancomycin monotherapy 6 (46.2) 69 (29.1)
1GC monotherapy 1 (7.7) 9 (3.8)
Vancomycin  nafcillin 3 (23.1) 35 (14.8)
Other 0 40 (16.8)
Definitive therapy 0.26
1GC 8 (61.5) 181 (76.4)
Nafcillin 5 (38.4) 32 (13.5)
Clindamycin 0 14 (5.9)
Other 0 10 (4.2)
Oral antibiotic at discharge 5 (38.5) 120 (50.6) 0.57
Duration of intravenous antibiotics (days) 22.5 (10–55) 14.5 (6–34) 0.17
Total duration of antibiotics (days) 46 (32–61) 42 (31–53) 0.71
Surgical management
Surgical procedure performed 11 (84.6) 145 (61.2) 0.14
2 surgical procedures 7 (53.8) 38 (15.8) 0.003
Delayed first source control 4 (30.7) 22 (9.2) 0.03
Duration of follow-up (days) 61 (32–82) 79 (36–285) 0.15
aAll continuous variables are presented as medians with interquartile ranges; categorical variables are presented as n (%).
bOther with regard to race includes Native American/Alaskan Native, Native Hawaiian/Pacific Islander, and self-identified multiple races.
cOnly 61 cases had abscess size documented.
TABLE 5 Multivariable analyses of risk factors for MSSA chronic osteomyelitisa
Factor Multivariable P value Adjusted OR 95% CI
Bone abscess 0.54 1.58 0.37–6.7
Positive blood culture 0.09 4.1 0.8–20.26
2 surgical procedures 0.01 6.99 1.58–31.1
Delayed first source control 0.03 2.59 1.16–11.11
agrIII 0.04 1.71 1.03–7.81
CzIE 0.03 13.4 1.1–18.21
aOR, odds ratio; CI, confidence interval.
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AHO caused by CzIE MSSA have similar rates of progression to chronic osteomyelitis
when treated with either 1GC or non-1GC regimens. These results suggest that poor
outcomes previously observed with CzIE strains may more accurately reflect some
intrinsic virulence factor rather than antibiotic failure per se, as negative outcomes
occurred irrespective of antibiotic choice. Such findings may explain why 1GCs and
antistaphylococcal penicillins have been found to have a similar overall efficacy in the
treatment of serious MSSA infections (3–5) despite the existence of CzIE in 10% to 20%
of North American MSSA isolates (29). Based on the results of the present study,
clinicians may be able to successfully use 1GCs to treat CzIE osteoarticular MSSA
infections, although careful follow-up is urged. Arguably, 1GCs may be the preferred
agent even in the setting of CzIE, given their favorable side effect profile relative to
antistaphylococcal penicillins; the rate of adverse drug reactions was almost 3-fold
higher among adults receiving nafcillin than those receiving cefazolin in one study (8).
FIG 3 Relationship between CzIE, definitive antibiotic choice, and development of chronic osteomyelitis.
Higher rates of chronic osteomyelitis were observed among CzIE isolates regardless of whether patients
were treated with a 1GC or an alternative agent. Comparisons performed with Fisher’s exact test.
FIG 4 Phylogenetic tree of CzIE isolates. Whole-genome sequencing from a total of 36 CzIE strains was
used to identify single nucleotide polymorphisms relative to the ST30 reference strain (GenBank
accession number CP022900) core genome, as described in the Materials and Methods. Node shape
(diamonds versus circles) corresponds to isolates with progression to chronic osteomyelitis, while color
indicates sequence type (ST; legend). Metadata layers are indicated and defined in the legend; final
metadata layer indicates geographic site of isolate, with light blue corresponding to TCH and dark blue
representing SLCH.
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Our findings must be interpreted with caution given the relatively small number of
patients in the present study who received definitive treatment with a non-1GC
regimen. Furthermore, these results are in direct contrast to work in adults by Lee et al.
(31) which showed that CzIE MSSA infections treated with cefazolin were associated
with higher rates of treatment failure than those treated with nafcillin. Interestingly,
these investigators found that CzIE and non-CzIE MSSA infections have overall similar
outcomes. In addition, studies in rat endocarditis models demonstrate that the use of
cefazolin in a CzIE MSSA infection is associated with a more severe disease course which
may be ameliorated by the addition of a -lactamase inhibitor with the 1GC (26, 32).
Such discrepancies could in part be related to differences in populations studied (adults
with comorbidities versus otherwise healthy children), as well as measures of treatment
success/failure. Definitively addressing this question would require a clinical trial com-
paring the outcomes of CzIE MSSA infections treated with antistaphylococcal penicillins
versus those with 1GC; however, significant challenges would exist for the execution of
such a study. Of note, the majority of patients in our study receiving a 1GC were treated
with cephalexin at an every-8-hour dosing interval with a median dose of 100 mg/kg/
day. Studies from the 1970s found that cephalexin peak serum concentrations in
children following a 25 mg/kg dose were 20 to 25 g/ml (33). Given the cephalexin
MIC90 of 8 g/ml, concerns may exist about the potential failure of this particular
therapy; however, the observed MIC range for cephalexin was similar to that found by
other investigators (18). Furthermore, a recent observational study at Rady Children’s
found that patients with MSSA AHO treated with cephalexin at a median of 91 mg/kg/
day had similar cure rates when doses were administered with either every 8 h or every
6 h (34). For our study, all patients received some duration of intravenous therapy and
many underwent surgical drainage procedures prior to starting cephalexin; these
interventions may have reduced the bacterial load enough to obviate CzIE.
The agrIII strains were also associated with chronic osteomyelitis. agr is a complex
quorum sensing regulatory system controlling the expression of numerous staphylo-
coccal adhesins and virulence factors (35). Isolates exhibiting agr dysfunction and
dysregulation of downstream gene products have previously been associated with
progression to chronic infection in animal models of osteomyelitis (36). While we did
not specifically assess for agr dysfunction, differences in agr-associated gene regulation
attributable to specific agr polymorphisms may partially explain our findings. Interest-
ingly, agrIII is rarely associated with community-acquired methicillin-resistant S. aureus
(MRSA) in the United States, with most USA300 strains (either MRSA or MSSA) being
agrI (21, 24). Approximately 25% of invasive non-USA300 MSSA strains belong to agrIII
(21) and thus may represent a small but virulent subset of MSSA. USA300 strains have
previously been associated with large purulent collections (19) that often require
multiple debridement procedures; this may explain in part why CzIE strains (which are
most frequently agrIII) are less often associated with multiple debridements.
Based on whole-genome sequencing studies, the most common sequence type
among CzIE isolates was ST30, accounting for nearly half of all strains, which is
consistent with work from South America (9). Interestingly, previous research examin-
ing all invasive MSSA in children found that ST30 strains only account for 10% of all
disease (21). Taken together, these data suggest that strain background may be
important in at least a subset of CzIE isolates. Notably, the overwhelming majority of
ST30 CzIE isolates possessed type A -lactamase, which is known to have the highest
affinity for 1GCs (13, 14).
Additional limitations to this study should be acknowledged. Foremost, the retro-
spective nature of the study limits the degree to which conclusions can be made
regarding therapeutic decisions and outcomes. The unequal contribution of cases by
the two sites may have potentially introduced bias, and moreover, all MSSA osteomy-
elitis may not have been captured. Notably, the proportion of cases with CzIE was
similar at both study institutions. The rate of chronic osteomyelitis in this study (5.2%)
was higher than that reported in some centers but was overall consistent with the
range reported across North American studies (20, 37); our study utilized a broad
Cefazolin Inoculum Effect in Pediatric MSSA Antimicrobial Agents and Chemotherapy
September 2020 Volume 64 Issue 9 e00703-20 aac.asm.org 9
 on S
eptem










definition of chronic osteomyelitis that incorporated clinical, pathological, and radio-
graphic criteria (24) to provide a thorough capture of sequelae. The high degree of
surgical source control at the participating study sites may not accurately reflect wider
pediatric practice and may have influenced the impact of CzIE on outcomes. Similarly,
the fact that the majority of patients received a non-1GC regimen empirically may have
impacted disease burden sufficiently to influence the observed relationship between
CzIE, 1GC use, and outcome. It is difficult retrospectively to account for the potential
impact of postdischarge medication adherence on outcomes. Furthermore, clinical
microbiology laboratories do not routinely screen MSSA isolates for CzIE, limiting the
impact our findings have on management at the bedside. The relatively labor-intensive
nature of the broth macrodilution assay may make implementation difficult for many
busy clinical laboratories. The study is underpowered to explore the relationship
between dosing of 1GCs, CzIE, and outcome. Finally, as this study focused on AHO, the
findings may not necessarily be extrapolated to other invasive MSSA infections in
children.
In conclusion, CzIE is exhibited by 14% of MSSA isolates at 2 geographically distinct
pediatric centers. CzIE is associated with clindamycin resistance as well as specific
genotypes which include agrIII/ST30. CzIE, along with delayed source control and the
need for multiple surgical procedures in MSSA AHO, is associated with progression to
chronic osteomyelitis. Further work is needed to better understand the relationship
between CzIE and negative outcomes, as well as how or if this phenomenon should
impact therapeutic decisions.
MATERIALS AND METHODS
Isolates and patients were identified through two separate ongoing surveillance studies at Texas
Children’s Hospital (TCH; affiliated with Baylor College of Medicine, Houston, TX, comprising 724
inpatient beds) (38) and St. Louis Children’s Hospital (SLCH; affiliated with Washington University School
of Medicine, St. Louis, MO, with 390 inpatient beds) (39). At TCH, since 2001, all S. aureus isolates
identified by the clinical microbiology laboratory in the routine course of care are subcultured and stored
in horse blood at – 80°C in the Edward O. Mason, Jr., Infectious Diseases Research Laboratory (IDRL), and
basic clinical and demographic data are recorded on a standardized case report form (19). In previous
studies at our institution, MSSA accounted for 43% of all osteomyelitis cases, with the surveillance study
capturing 70% of these isolates (40). During the same time period, at SLCH, S. aureus isolates recovered
from the blood, bone, or synovial fluid were obtained from the clinical microbiology laboratory and
stored at – 80°C, and similar clinical data were recorded. Only one isolate per patient per episode of
infection was collected, and isolates were not serially passaged. For the purposes of this study, only
patients with culture-confirmed MSSA AHO with or without concomitant septic arthritis identified from
1 January 1 2011 to 31 December 2018 were included. The diagnosis of AHO was defined by a
constellation of physical examination, radiology, and microbiological findings as previously described
(19, 40, 41). Patients with open or penetrating trauma, orthopedic hardware in situ, or osteomyelitis
secondary to a contiguous focus or a surgical procedure (such as sternal osteomyelitis after cardiac
surgery) were excluded. Data from a subset of these patients have been reported in other publications
(19, 24, 39, 42). All medical records were reviewed from the time of initial hospital admission with AHO
until time of last follow-up with infectious diseases or orthopedics. The institutional review boards of
Baylor College of Medicine and Washington University School of Medicine approved this study. A full
description of study definitions and the genomic and statistical analyses are provided in Appendix S1 in
the supplemental material.
Microbiology studies. The clinical microbiology labs at TCH and SLCH performed initial isolate
identification as well as susceptibility testing to oxacillin, vancomycin, and clindamycin in accordance
with CLSI guidelines (43). Additional characterization of isolates as well as microbiology studies were
performed in the IDRL at TCH. All isolates underwent testing for the presence of CzIE using paired
cefazolin broth macrodilution assays with an inoculum of 105 CFU/ml (standard inoculum to confirm
susceptibility) and 107 CFU/ml (high inoculum) (additional detail in Appendix S1). Current CLSI guidelines
do not define 1GC breakpoints for S. aureus. CzIE was defined as a cefazolin MIC of 16 g/ml using the
107 CFU/ml inoculum (9, 23); this value was regarded as a clinically significant MIC, as previous 2012
guidelines defined cefazolin susceptibility in S. aureus as an MIC of 8 g/ml (28). All isolates exhibiting
CzIE as well as an equivalent number of random non-CzIE isolates were also subjected to cephalexin MIC
determinations using high and low inocula, as described above. Laboratory personnel performing CzIE
testing were blind to all clinical data.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.3 MB.
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